: CONMED Corporation Todd Garner Chief Financial Officer 315-624-3317 ToddGarner@conmed.com CONMED Corporation Announces First Quarter 2018 Financial Results Utica, New York

CONMED Corporation Announces

First Quarter 2018 Financial Results

Utica, New York, April 25,

2018 --- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the first quarter ended March 31, 2018.

First Quarter 2018 Highlights

"We are pleased with our first

quarter results, in which we delivered 6.8% constant-currency revenue growth and 13.9% adjusted EBITDA growth over the prior year,"

commented Curt R. Hartman, CONMED's President and Chief Executive Officer. "Looking forward, we are increasing our

outlook for 2018, while continuing to invest back into the business to strengthen the long-term revenue and earnings profile of

For the quarter ended March 31,

2018, domestic sales, which represented 52.6% of total revenue, increased 6.9% on a reported basis, driven by solid performances

in both General Surgery and Orthopedics. On January 1, 2018, the Company began adjusting its sales for administrative fees by recording

these fees as a reduction of revenue under ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09").

For the first quarter of 2017, these administrative fees totaled $1.7 million. As a result, on an adjusted(1) basis,

domestic sales increased 8.7% year over year.

International sales, which represented

47.4% of total revenue, increased 10.0% compared to the first quarter of 2017 on a reported basis. Foreign currency exchange rates,

including the effects of the FX hedging program, had a positive impact of $4.6 million on first quarter sales. In constant currency,

international sales increased 4.7% versus the prior-year period.

For the quarter ended March 31,

2018, reported net earnings totaled $10.7 million, compared to a reported net loss of $4.5 million a year ago. Reported diluted

net earnings per share were $0.37 in the quarter, compared to reported diluted net loss per share of $0.16 in the prior-year period.

Reported net loss for 2017 includes restructuring costs, business acquisition costs, and legal costs. Reported net income for the

first quarter of 2018 includes a tax expense of $0.3 million resulting from adjustments to the December 2017 tax balances related

to the 2017 Tax Cuts and Jobs Act. The effect of each of these items on reported net income (loss) and reported diluted net earnings

(loss) per share appears in the reconciliation of GAAP to non-GAAP measures below.

The Company excludes the costs of

special items, including acquisitions, restructurings, legal matters, gains on the sale of assets, debt refinancings, amortization

of intangible assets, net of tax, as well as adjustments to the December 2017 tax balances and provisional income tax effects of

the 2017 Tax Cuts and Jobs Act, from its adjusted diluted net earnings per share. Excluding the impact of these items, adjusted

net earnings(3) of $15.1 million increased 42.7% year over year, and adjusted diluted net earnings per share(2)

of $0.53 increased 39.5% year over year. The increase in adjusted net earnings(3) resulted primarily from higher sales,

the favorable impact of foreign exchange rates, improved operating margin and a lower effective tax rate.

Based on current business trends,

CONMED is raising its previously issued financial guidance. The Company now expects full-year 2018 constant-currency sales growth

in the range of 4.5% to 5.5%, compared to the previous range of 4.0% to 5.0%. Based on recent exchange rates, the positive impact

to 2018 sales from foreign exchange is anticipated to be between 100 and 150 basis points, which is consistent with the Company's

previously issued guidance.

The Company now forecasts full-year

2018 adjusted diluted net earnings per share in the range of $2.15 to $2.20, compared to the previous range of $2.11 to $2.17.

This represents growth over 2017 of approximately 14% to 16%. The adjusted diluted net earnings per share estimates for 2018 exclude

the cost of special items, including acquisition costs and restructuring costs, which are estimated in the range of $3 to $5 million,

net of tax, and amortization of intangible assets, which are estimated in the range of $16 to $18 million, net of tax.

Supplemental Financial Disclosures

(1) Adjusted net sales

growth is measured in constant currency and is adjusted for administrative fees that the Company began recording as a reduction

of revenue under ASU 2014-09, Revenue from Contracts with Customers, effective January 1, 2018; 2017 administrative fees totaled

$1.7 million for the period and were all related to domestic sales.

(2) A reconciliation

of reported diluted net earnings (loss) per share to adjusted diluted net earnings per share, a non-GAAP financial measure, appears

(3) A reconciliation

of reported net income (loss) to adjusted net earnings, a non-GAAP financial measure, appears below.

The Company's management will

host a conference call today at 4:30 p.m. ET to discuss its first quarter 2018 results.

To participate in the conference

call, dial 844-889-7792 (domestic) or 661-378-9936 (international)

and refer to the passcode 3682039.

This conference call will also be

webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com.

The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also

be available from 7:30 p.m. ET on Wednesday, April 25, 2018, until 7:30 p.m. ET on Wednesday, May 9, 2018. To hear this recording,

dial 855-859-2056 (domestic) or 404-537-3406 (international) and enter the passcode 3682039.

About CONMED Corporation

CONMED is a medical technology company

that provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons

and physicians in a variety of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology.

CONMED has a direct selling presence in 19 countries, and international sales constitute approximately 50% of the Company's

total sales. Headquartered in Utica, New York, the Company employs approximately 3,100 people. For more information, visit www.conmed.com.

Forward-Looking Statements

This press release and today's

conference call may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties,

which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements

herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause

actual results to differ materially from those in the forward-looking statements may include, but are not limited to, the risk

factors discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Any and all forward-looking

statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to

the Company's performance on a going-forward basis. The Company believes that all forward-looking statements made by it have

a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in

the forward-looking statements will actually occur or prove to be correct.

Supplemental Information - Reconciliation

of GAAP to Non-GAAP Financial Measures

The Company supplements the reporting

of its financial information determined under accounting principles generally accepted in the United States (GAAP) with certain

non-GAAP financial measures, including percentage sales growth in constant currency and as adjusted for ASU 2014-09; adjusted gross

profit; cost of sales excluding specified items; adjusted selling and administrative expenses; adjusted operating income; adjusted

income tax expense; adjusted effective income tax rate; adjusted net earnings and adjusted diluted net earnings per share (EPS).

The Company believes that these non-GAAP measures provide meaningful information to assist investors and shareholders in understanding

its financial results and assessing its prospects for future performance. Management believes percentage sales growth as adjusted

for ASU 2014-09 and in constant currency and the other adjusted measures described above are important indicators of its operations

because they exclude items that may not be indicative of, or are unrelated to, its core operating results and provide a baseline

for analyzing trends in the Company's underlying business. Further, the presentation of EBITDA is a non-GAAP measurement

that management considers useful for measuring aspects of the Company's cash flow. Management uses these non-GAAP financial

measures for reviewing the operating results and analyzing potential future business trends in connection with its budget process

and bases certain management incentive compensation on these non-GAAP financial measures.

Net sales on an "adjusted"

basis is a non-GAAP measure that presents net sales in "constant currency" and adjusts for the adoption impact of ASU

2014-09. The Company analyzes net sales on a constant currency basis to better measure the comparability of results between periods.

To measure percentage sales growth in constant currency, the Company removes the impact of changes in foreign currency exchange